A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy (NCT06979362)
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
🩺 Plain-English Summary (8th-Grade Level)
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (12 items).
Location: Univ of Alabama Birmingham — Birmingham, Alabama
Age range: 40 Years to 84 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Estimated glomerular filtration rate lesser than (\<) 30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at time of screening, measured by central laboratory
- Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation
- Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening
- Participants receiving intravenous HF medications within 45 days prior to randomisation
- Participants with CRT, pacemaker or implantable cardioverter-defibrillator
- Planned coronary revascularisation, pacemaker/cardioverter-defibrillator/CRT implantation, ablation of cardiac arrythmias and valve repair/replacement at the time of randomisation
- Stroke or transient ischemic attack within 12 months prior to randomisation
- Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator
- Known history of severe liver disease and/or alanine aminotransferase or aspartate aminotransferase \>2.5 x upper limit of normal at screening, measured by central laboratory
- Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy \[HCM\]).
- Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (117 Sites)
Showing the first 25 of 117 sites.
- Univ of Alabama Birmingham — Birmingham, Alabama
- TMC Hlthcr Clin Res Office — Tucson, Arizona
- Pima Heart and Vascular — Tucson, Arizona
- Valley Clinical Trials — Covina, California
- UCSD NAFLD Research Center — La Jolla, California
- Valley Clinical Trials — Northridge, California
- University of California, San Francisco — San Francisco, California
- University of California San Francisco UCSF — San Francisco, California
- Harbor-UCLA Medical Center — Torrance, California
- Univ of Colorado at Denver — Aurora, Colorado
- Inpatient Research Clinic LLC — Miami Lakes, Florida
- AdventHealth Orlando — Orlando, Florida
- Guardian Research Org LLC — Winter Park, Florida
- UofL Health Care Outpatient — Louisville, Kentucky
- Henry Ford Hospital_Detroit — Detroit, Michigan
- University of Minnesota_Minneapolis_1 — Minneapolis, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Icahn Sch of Med-Mt Sinai Hosp — New York, New York
- Duke University — Durham, North Carolina
- Providence St. Vincent Heart — Portland, Oregon
- Abington Memorial Hospital — Abington, Pennsylvania
- Capital Area Research LLC — Camp Hill, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- Amarillo Medical Specialists — Amarillo, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (866) 867-7178
Email: clinicaltrials@novonordisk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure
- REDUCE LAP-HFREF TRIAL — New York, New York
- Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart Failure in the Guadeloupe Archipelago Between the University Hospital of Guadeloupe and the Marie-Galante Hospital — Grand-Bourg,
- Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
- Staged Kidney Transplantation During Combined Heart/Kidney Transplantation — Los Angeles, California
- Alleviant ALLAY-HFrEF Study — Los Angeles, California
Explore by condition: All Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.